[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612021":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":28,"responsibleParty":44,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":22,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":22,"enrollmentInfo":59,"targetDuration":22,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":22,"overallStatus":31,"whyStopped":22,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Bioray Laboratories","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","5×10\\^6\u002FkgBW",[13],"Drug: BRL-301",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","BRL-301","The administered dose is 5×10\\^6\u002Fkg",[9],[21],"Allogeneic Chimeric Antigen Receptor T-Cell Injection Targeting the CD19 Gene",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":22},"Ping Li, phD","CONTACT","13564181131",[29],{"facility":30,"status":31,"city":32,"state":22,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Shanghi Tongji Hospital (Tongji Hospital of Tongji University)","RECRUITING","Shanghai","620000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],121.45806,31.22222,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":22},{"type":45,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[47],{"name":48,"class":49},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER","100612021","universal-car-t-cell-therapy-for-nhl-100612021",false,"NCT07248163","Universal CAR-T Cell Therapy for NHL","A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting CD19 in the Treatment of r\u002Fr B Lymphocyte Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Willing to participate in this clinical study and sign an informed consent form;\n2. Age ≥ 18 years old;\n3. Estimated survival time ≥ 3 months;\n4. At least one measurable lesion;\n5. CD19 positively expressed;\n6. ECOG score 0-1；\n7. Hematology, coagulation and biochemistry parameters meeting the requirements;\n8. LVEF ≥ 55%;\n9. No severe pulmonary disorders;\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Subjects who previously received allogeneic cell therapies, including allogeneic stem cell transplant;\n3. Subjects who previously received anti-CD19 targeted therapy;\n4. Prior treatment with any CAR-T cell product or other genetically modified T cell therapies;\n5. History of Richter's transformation of chronic lymphocytic leukemia (CLL);\n6. Presence of uncontrollable fungal, bacterial, viral, or other infections requiring systemic therapy;\n7. Subjects with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA titer higher than the upper limit of detection; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;\n8. Severe mental disorders; history of CNS disorders (e.g., epileptic seizure, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar diseases, or any CNS-involved autoimmune disorders);\n9. Active autoimmune disorders requiring immunotherapy, including but not limited to end organ damages caused by autoimmune disorders (e.g., Crohn's disease, rheumatoid arthritis, and systemic lupus erythematosus) in the past 2 years, or requiring systemic application of immunosuppressive drugs or other drugs for systemic control of diseases;\n10. Primary immunodeficiency;\n11. History of other malignancies;\n12. Patients with severe cardiovascular disorders;\n13. Any circumstances that possibly increase the risk of subjects or interfere with the study results as judged by the investigator.","ALL","18 Years",{"count":60,"type":61},6,"ESTIMATED","INTERVENTIONAL",[64],"NA","This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.",[67],"Non-hodgkin Lymphoma,B Cell","2025-11-18",{"date":70,"type":71},"2025-11-25","ACTUAL",{"date":73,"type":71},"2025-03-11",{"date":75,"type":61},"2028-03-11",{"name":5,"class":6},1]